109 Matching Annotations
  1. Last 7 days
  2. May 2021
    1. David Benkeser. (2020, November 9). Another view on uncertainty associated based on Pfizer’s results. Even if you were highly skeptical about MRNA vaccines (many are [were?]) with 50% prior belief that VE ~ 0, based on an 8:86 vax:placebo case split, the posterior probability that VE > 75% is ~ 1. Https://t.co/xtBONtGHmT [Tweet]. @biosbenk. https://twitter.com/biosbenk/status/1325856366225993729

    1. Hilda Bastian, PhD. (2021, February 6). Unofficial unnamed AstraZeneca insider says they are doing the interim analysis for the US trial of the Oxford vaccine. AstraZeneca spokesperson says 4-6 weeks till data release. Https://t.co/VUHgbHN02d One is wrong? Or they’ll release only when have FDA minimum follow-up? Https://t.co/LgjfX8AIti [Tweet]. @hildabast. https://twitter.com/hildabast/status/1357862227106095105

    1. Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B. J., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E., Collins, A. M., Cox, T., Darton, T., Dold, C., Douglas, A. D., Duncan, C. J. A., Ewer, K., Flaxman, A., … Group, O. C. V. T. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (SSRN Scholarly Paper ID 3779160). Social Science Research Network. https://doi.org/10.2139/ssrn.3779160

  3. Apr 2021
    1. Eric Topol on Twitter: “The variants of concern/interest fall into a spectrum of immune evasiveness, w/ B.1.351 being most; B.1.1.7, B.1.429 least. This property pertains to potential for reinfection & some reduction in vaccine efficacy My prelim estimates based on publications/preprints, subject to Δ https://t.co/fQZwBCUEGS” / Twitter. (n.d.). Retrieved April 28, 2021, from https://twitter.com/EricTopol/status/1380203664317456385

    1. Mehdi Hasan. (2021, April 12). ‘Given you acknowledged...in March 2020 that Asian countries were masking up at the time, saying we shouldn’t mask up as well was a mistake, wasn’t it... At the time, not just in hindsight?’ My question to Dr Fauci. Listen to his very passionate response: Https://t.co/BAf4qp0m6G [Tweet]. @mehdirhasan. https://twitter.com/mehdirhasan/status/1381405233360814085

  4. Mar 2021
    1. Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B. J., Baillie, V., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Clutterbuck, E., Collins, A. M., Cutland, C., Darton, T., Dheda, K., Douglas, A. D., … Group, O. C. V. T. (2021). Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine (SSRN Scholarly Paper ID 3777268). Social Science Research Network. https://papers.ssrn.com/abstract=3777268

    1. Yufika, A., Wagner, A. L., Nawawi, Y., Wahyuniati, N., Anwar, S., Yusri, F., Haryanti, N., Wijayanti, N. P., Rizal, R., Fitriani, D., Maulida, N. F., Syahriza, M., Ikram, I., Fandoko, T. P., Syahadah, M., Asrizal, F. W., Aletta, A., Haryanto, S., Jamil, K. F., … Harapan, H. (2020). Parents’ hesitancy towards vaccination in Indonesia: A cross-sectional study in Indonesia. Vaccine, 38(11), 2592–2599. https://doi.org/10.1016/j.vaccine.2020.01.072

    1. .The firstparadigm centres on institutional power: ‘Our schools, our government, our businessesand corporations are permeated with the view that neither individual nor group aretrustworthy. There must be power over, power to control. This hierarchal system isinherent in our whole culture’. The second paradigm takes the opposite view: ‘Givena suitable climate, humankind is trustworthy, creative, self-motivated, powerful andconstructive – capable of releasing undreamed-of-potentialities’

      there is an ongoing struggle in many areas of society, in schools, workplaces, religious organisations. the second paradigm doesn't seem to win over the first on a large scale, since significant change in any domain is a frustrating and never-ending process.

    2. importedfrom the business and commercial world.

      who decided this? who decides which measures of success are appropriate?

    3. target driven climate which has the potential to undermine theimportance of ‘relationship

      taking away from the very purpose of the practice



  5. Feb 2021
    1. Carl T. Bergstrom. (2021, January 31). A somewhat technical thread about measuring vaccine efficacy. We’re used to the notion that certain properties of tests for disease depend on prevalence: Positive and negative predictive value do, for example, whereas sensitivity and specificity do not. [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1355762090078703621

    1. Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Lambson, B. E., Vermeulen, M., Berg, K. van den, Rossouw, T., Boswell, M., Ueckermann, V., Meiring, S., Gottberg, A. von, Cohen, C., Morris, L., Bhiman, J. N., & Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. BioRxiv, 2021.01.18.427166. https://doi.org/10.1101/2021.01.18.427166

  6. Jan 2021
    1. ReconfigBehSci. (2020, November 9). RT @peterbachmd: Relevant today: Ever sharp @nataliexdean on Vaccine Effectiveness vs Efficacy from many moons ago (i.e. About a month). Sh… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1325889181097267200

  7. Dec 2020
    1. Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

  8. Nov 2020
  9. Oct 2020
    1. Preservice Teacher Experience with Technology Integration: How the Preservice Teacher’s Effica-cy in Technology Integration is Impactedby the Context of the Preservice Teacher Education Pro-gram

      This article discusses the need for teacher education to focus just as much on technology knowledge (regardless of grade level taught) as on educational theory and methods. It argues that teachers cannot be effective if they are not trained in not only current technologies, but also taught to be familiar with navigating new technologies as the emerge. 5/10 Very specific to K-12 teacher education.

  10. Sep 2020
    1. Natalie E. Dean en Twitter: “VACCINE EFFICACY 101: A biostatistician's primer. Ten tweets to cover:- How is vaccine efficacy calculated?- Distinguishing between infection, disease, & severe disease.- Measuring reduced infectiousness.- Vaccine efficacy vs. effectiveness!n” / Twitter. (n.d.). Twitter. Retrieved September 30, 2020, from https://twitter.com/nataliexdean/status/1310613702476017666

    1. Siemieniuk, R. A., Bartoszko, J. J., Ge, L., Zeraatkar, D., Izcovich, A., Kum, E., Pardo-Hernandez, H., Rochwerg, B., Lamontagne, F., Han, M. A., Liu, Q., Agarwal, A., Agoritsas, T., Chu, D. K., Couban, R., Darzi, A., Devji, T., Fang, B., Fang, C., … Brignardello-Petersen, R. (2020). Drug treatments for covid-19: Living systematic review and network meta-analysis. BMJ, 370. https://doi.org/10.1136/bmj.m2980

  11. Aug 2020
    1. Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., Wu, S.-P., Wang, Z., Wu, X.-H., Xu, J.-J., Zhang, Z., Jia, S.-Y., Wang, B.-S., Hu, Y., Liu, J.-J., … Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)31605-6